<?xml version="1.0" encoding="UTF-8" standalone="no" ?><xml><records><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hendaus,M.A.</style></author><author><style face="normal" font="default"> Jomha,F.A.</style></author><author><style face="normal" font="default"> Alhammadi,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Section of Academic General Pediatrics, Hamad Medical Corporation, Doha, Qatar; Department of Clinical Pediatrics, Weill Cornell Medical College in Qatar, Doha, Qatar</style></auth-address><titles><title><style face="normal" font="default">Is ketamine a lifesaving agent in childhood acute severe asthma?</style></title><secondary-title><style face="normal" font="default">Ther Clin Risk Manag</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ther Clin Risk Manag</style></abbr-1></periodical><pages end="279" start="273">273-279</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Qatar</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Children with acute severe asthma exacerbation are at risk of developing respiratory failure. Moreover, conventional aggressive management might be futile in acute severe asthma requiring intubation and invasive ventilation. The aim of this review is to detail evidence on the use of ketamine in childhood asthma exacerbations. A search of the MEDLINE, EMBASE, and Cochrane databases was performed, using different combinations of the following terms: ketamine, asthma, use, exacerbation, and childhood. In addition, we searched the references of the identified articles for additional articles. We then reviewed titles and included studies that were relevant to the topic of interest. Finally, the search was limited to studies published in English and Spanish from 1918 to June 2015. Due to the scarcity in the literature, we included all published articles. The literature reports conflicting results of ketamine use for acute severe asthma in children. Taking into consideration the relatively good safety profile of the drug, ketamine might be a reasonable option in the management of acute severe asthma in children who fail to respond to standard therapy. Furthermore, pediatricians and pediatric emergency clinicians administering ketamine should be knowledgeable about the unique actions of this drug and its potential side effects</style></abstract><notes><style face="normal" font="default">DA - 20160309IS - 1176-6336 (Print)IS - 1176-6336 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Qatar -CO - Lebanon -</style></notes><work-type><style face="normal" font="default">10.2147/TCRM.S100389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26955277">PM:26955277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ther Clin Risk Manag\2016-12-273-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ther Clin Risk Manag\2016-12-273-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160309, Hendaus MA</style></custom2><misc3><style face="normal" font="default">10.2147/TCRM.S100389</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hendaus,M.A.</style></author><author><style face="normal" font="default"> Jomha,F.A.</style></author><author><style face="normal" font="default"> Ehlayel,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Section of Academic General Pediatrics, Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medical College, Doha, Qatar</style></auth-address><titles><title><style face="normal" font="default">Allergic diseases among children: nutritional prevention and intervention</style></title><secondary-title><style face="normal" font="default">Ther Clin Risk Manag</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ther Clin Risk Manag</style></abbr-1></periodical><pages end="372" start="361">361-372</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Amino acid</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Bifidobacterium</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Breast Feeding</style></keyword><keyword><style face="normal" font="default"> Breast-feeding</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Micronutrients</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prebiotics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Qatar</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Allergic diseases comprise a genetically heterogeneous group of chronic, immunomediated diseases. It has been clearly reported that the prevalence of these diseases has been on the rise for the last few decades, but at different rates, in various areas of the world. This paper discusses the epidemiology of allergic diseases among children and their negative impact on affected patients, their families, and societies. These effects include the adverse effects on quality of life and economic costs. Medical interest has shifted from tertiary or secondary prevention to primary prevention of these chronic diseases among high-risk infants in early life. Being simple, practical, and cost-effective are mandatory features for any candidate methods delivering these strategies. Dietary therapy fits this model well, as it is simple, practical, and cost-effective, and involves diverse methods. The highest priority strategy is feeding these infants breast milk. For those who are not breast-fed, there should be a strategy to maintain beneficial gut flora that positively influences intestinal immunity. We review the current use of probiotics, prebiotics, and synbiotics, and safety and adverse effects. Other dietary modalities of possible potential in achieving this primary prevention, such as a Mediterranean diet, use of milk formula with modified (hydrolyzed) proteins, and the role of micronutrients, are also explored. Breast-feeding is effective in reducing the risk of asthma, allergic rhinitis, and atopic eczema among children. In addition, breast milk constitutes a major source of support for gut microbe colonization, due to its bifidobacteria and galactooligosaccharide content. The literature lacks consensus in recommending the addition of probiotics to foods for prevention and treatment of allergic diseases, while prebiotics may prove to be effective in reducing atopy in healthy children. There is insufficient evidence to support soy formulas or amino acid formulas for prevention of allergic disease. A healthy diet, such as the Mediterranean diet, may have a protective effect on the development of asthma and atopy in children. In children with asthma and allergic diseases, vitamin D deficiency correlates strongly with asthma, allergic rhinitis, and wheezing</style></abstract><notes><style face="normal" font="default">DA - 20160329IS - 1176-6336 (Print)IS - 1176-6336 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Qatar -CO - Lebanon -</style></notes><work-type><style face="normal" font="default">10.2147/TCRM.S98100</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27022267">PM:27022267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ther Clin Risk Manag\2016-12-361-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ther Clin Risk Manag\2016-12-361-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160329, Hendaus MA</style></custom2><misc3><style face="normal" font="default">10.2147/TCRM.S98100</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,X.Y.</style></author><author><style face="normal" font="default"> Lim-Jurado,M.</style></author><author><style face="normal" font="default"> Prepageran,N.</style></author><author><style face="normal" font="default"> Tantilipikorn,P.</style></author><author><style face="normal" font="default"> Wang,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of ChinaSt Luke's Medical Center, Quezon City, Manila, PhilippinesDepartment of Otorhinolaryngology, Head &amp; Neck Surgery, University Malaya Faculty of Medicine, Kuala Lumpur, MalaysiaRhinology and Allergy Division, Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="default">Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine</style></title><secondary-title><style face="normal" font="default">Ther Clin Risk Manag</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ther Clin Risk Manag</style></abbr-1></periodical><pages end="597" start="585">585-597</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Philippines</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients' quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug-drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug's safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria</style></abstract><notes><style face="normal" font="default">DA - 20160425IS - 1176-6336 (Print)IS - 1176-6336 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -CO - Philippines -CO - Thailand -CO - Malaysia -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.2147/TCRM.S105189</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27110120">PM:27110120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ther Clin Risk Manag\2016-12-585-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ther Clin Risk Manag\2016-12-585-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160425, Wang XY</style></custom2><misc3><style face="normal" font="default">10.2147/TCRM.S105189</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomas,A.J.</style></author><author><style face="normal" font="default"> Alt,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Oral Therapeutics for Rhinosinusitis with Nasal Polyposis</style></title><secondary-title><style face="normal" font="default">Adv Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Otorhinolaryngol</style></abbr-1></periodical><pages end="147" start="138">138-147</pages><volume><style face="normal" font="default">79</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Doxycycline</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene antagonist</style></keyword><keyword><style face="normal" font="default"> Leukotriene Antagonists</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Oral therapeutics for chronic rhinosinusitis with nasal polyps (CRSwNP) include oral corticosteroids (OCS), antibiotics, antifungals and anti-leukotrienes. Of these treatments, the strongest evidence exists to support the use of a short course of OCS for treatment of CRSwNP, and OCS are the most consistently recommended oral therapy in practice guidelines. Antibiotics have demonstrated some utility, which appears more likely related to an anti-inflammatory rather than antimicrobial effect. The non-macrolide antibiotics lack sufficient evidence to support their use, though among this class doxycycline has some limited evidence of benefit in CRSwNP. Greater evidence exists for the use of macrolide antibiotics which have shown reduction of subjective and objective measures of CRSwNP severity. A short course of a macrolide should be considered as an option. Oral antifungals are not recommended in the treatment of CRSwNP given disappointing results and known potential adverse effects, except in allergic fungal rhinosinusitis where they may play a role. Leukotriene antagonists have demonstrated some promise in the treatment of CRSwNP, though studies are limited, but should be considered a potentially useful oral therapeutic. The current level of evidence for these oral therapeutic options for CRSwNP is reviewed in this chapter</style></abstract><notes><style face="normal" font="default">DA - 20160729IS - 1662-2847 (Electronic)IS - 0065-3071 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1159/000445151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466856">PM:27466856</url></web-urls></urls><custom2><style face="normal" font="default">20160729, Thomas AJ</style></custom2><misc3><style face="normal" font="default">10.1159/000445151</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fruth,K.</style></author><author><style face="normal" font="default"> Gosepath,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Aspirin Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">Adv Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Otorhinolaryngol</style></abbr-1></periodical><pages end="28" start="21">21-28</pages><volume><style face="normal" font="default">79</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Aspirin exacerbated respiratory disease (AERD) has been defined as a non-steroidal anti-inflammatory drug (NSAID)-triggered hypersensitivity, non-allergic bronchial asthma and chronic rhinosinusitis (CRS) with nasal polyps. The underlying pathophysiology of AERD is not completely understood so far. An altered arachidonic acid metabolism and dysregulated enzyme activity are regarded to be causal. AERD is characterized by recalcitrant CRS with recurrent nasal polyps after sinus surgery, accompanied by difficult to treat bronchial asthma and adverse reaction after NSAID ingestion such as nasal blockage, itching, laryngospasm and severe asthma attacks. Affected individuals suffer from poor quality of life. Besides functional endoscopic sinus surgery, the application of topical and systemic steroids and symptomatic therapy, aspirin desensitization is the only causative treatment option. The diagnostic approach to AERD, the ideal desensitization protocol and especially the following daily maintenance dose is part of an ongoing debate. This article summarizes the current knowledge about the pathophysiology, focuses on modern diagnostic approaches of AERD and discusses various aspirin desensitization protocols with respect to efficacy as well as to undesirable side effects</style></abstract><notes><style face="normal" font="default">DA - 20160729IS - 1662-2847 (Electronic)IS - 0065-3071 (Linking)LA - engPT - Journal ArticleSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1159/000445093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466843">PM:27466843</url></web-urls></urls><custom2><style face="normal" font="default">20160729, Fruth K</style></custom2><misc3><style face="normal" font="default">10.1159/000445093</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Valk,P.J.</style></author><author><style face="normal" font="default"> Simons,R.</style></author><author><style face="normal" font="default"> Jetten,A.M.</style></author><author><style face="normal" font="default"> Valiente,R.</style></author><author><style face="normal" font="default"> Labeaga,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">TNO, Soesterberg, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude</style></title><secondary-title><style face="normal" font="default">Aerosp Med Hum Perform</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Aerosp Med Hum Perform</style></abbr-1></periodical><pages end="627" start="622">622-627</pages><volume><style face="normal" font="default">87</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Altitude</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Hydroxyzine</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> single dose</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vigilance</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Bilastine is a new oral, second generation antihistamine used in the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. It is considered a nonsedating antihistamine and might be recommended for use in pilots, pending research on the effects on flying-related performance under hypobaric conditions that prevail in an airliner. We assessed the effects of a single dose of bilastine 20 mg on alertness and complex task performance of healthy volunteers in a hypobaric chamber at 75.2 kPa (8000 ft/2438 m cabin altitude). METHODS: In a randomized, double-blind, crossover study, 24 volunteers received a single dose of bilastine 20 mg, hydroxyzine 50 mg (active control), and placebo. Using the Vigilance and Tracking Task, Multi-Attribute Task Battery, and Stanford Sleepiness Scale, assessments were made before and up to 6 h after intake of the study medication. RESULTS: Bilastine 20 mg had no impairing effects on sleepiness levels, vigilance, or complex task performance for up to 6 h post-dose. Hydroxyzine 50 mg (active control) was associated with significant sleepiness and impaired performance across this time period, confirming the sensitivity of the tests. CONCLUSION: Bilastine 20 mg did not cause sleepiness or impaired performance on tasks related to flying. It is anticipated that a single dose of bilastine 20 mg will not affect flying performance. Bilastine may provide a safe therapeutic alternative for pilots suffering from allergic rhinitis or urticaria. Our findings might also have implications for the treatment of allergic disorders of personnel involved in other safety-sensitive jobs. Valk PJL, Simons R, Jetten AM, Valiente R, Labeaga L. Cognitive performance effects of bilastine 20 mg during 6 hours at 8000 ft cabin altitude. Aerosp Med Hum Perform. 2016; 87(7):622-627</style></abstract><notes><style face="normal" font="default">DA - 20160809IS - 2375-6314 (Print)IS - 2375-6314 (Linking)LA - engPT - Journal ArticleSB - IMSB - SCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.3357/AMHP.4522.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27503042">PM:27503042</url></web-urls></urls><custom2><style face="normal" font="default">20160809, Valk PJ</style></custom2><misc3><style face="normal" font="default">10.3357/AMHP.4522.2016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Motosugi,U.</style></author><author><style face="normal" font="default"> Ichikawa,T.</style></author><author><style face="normal" font="default"> Sano,K.</style></author><author><style face="normal" font="default"> Onishi,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Radiology, University of Yamanashi, 1110 Shimokato, Chuo-shi, Yamanashi 409-3898, Japan</style></auth-address><titles><title><style face="normal" font="default">Acute Adverse Reactions to Nonionic Iodinated Contrast Media for CT: Prospective Randomized Evaluation of the Effects of Dehydration, Oral Rehydration, and Patient Risk Factors</style></title><secondary-title><style face="normal" font="default">AJR Am J Roentgenol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">AJR Am J Roentgenol</style></full-title></periodical><pages end="938" start="931">931-938</pages><volume><style face="normal" font="default">207</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> Dehydration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Osmotic Pressure</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="8" Year="2016">2016/8/17</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objective of our study was to determine the effects of dehydration and oral rehydration on the incidence of acute adverse reactions to iodinated contrast media administered during abdominal and pelvic CT in outpatients. SUBJECTS AND METHODS: For our prospective randomized study performed at a single institution, adult outpatients undergoing contrast-enhanced abdominal CT were randomly divided into a rehydration group (n = 2244 patients [1379 men and 865 women]; mean age, 65.2 years; age range, 18-90 years) and a control group (n = 3715 [2112 male patients and 1603 female patients]; mean age, 65.8 years; age range, 17-96 years), which included an age- and sex-matched subgroup (adjusted control group, n = 2244). The rehydration group received an oral rehydration solution (500 mL of liquid in which osmotic pressure is adjusted to enhance gastrointestinal absorption) before abdominal and pelvic CT. Patients were also divided into subclinically dehydrated (n = 997) and hydrated (n = 4962) groups according to their answers to a questionnaire that they completed before the CT examination. The patients were interviewed about contrast-induced adverse reactions before they left the CT room, and the reactions were categorized as allergiclike or physiologic. The incidence of reactions was compared between the rehydration and control groups and between the subclinical dehydration and hydrated groups. The rehydration and control groups were compared with an unpaired t test or a chi-square or Fisher test. RESULTS: The overall incidence of an acute adverse reaction was 4.3% (254/5959); the acute adverse reactions included 136 allergiclike and 118 physiologic reactions. Fourteen allergiclike and nine physiologic reactions were moderate grade, and none was severe. There was no significant difference between the rehydration group and adjusted control group in the overall incidence of adverse reactions (99/2244 [4.4%] vs 100/2244 [4.5%], respectively; p = 0.9422) or between the subclinically dehydrated group and hydrated group in the incidence of allergiclike reactions (25/997 [2.5%] vs 111/4962 [2.2%], p = 0.6062) and physiologic reactions (22/997 [2.2%] vs 96/4962 [1.9%], p = 0.5793). Younger age was a risk factor for both allergiclike and physiologic reactions (p &lt;/= 0.0019). CONCLUSION: Dehydration and oral rehydration did not affect the incidence of acute adverse reactions to iodinated contrast material for abdominal and pelvic CT in our randomized prospective trial</style></abstract><notes><style face="normal" font="default">DA - 20160817IS - 1546-3141 (Electronic)IS - 0361-803X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">10.2214/AJR.16.16051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27533472">PM:27533472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\AJR Am J Roentgenol\2016-207-931-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\AJR Am J Roentgenol\2016-207-931-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160817, Motosugi U</style></custom2><misc3><style face="normal" font="default">10.2214/AJR.16.16051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cantone,E.</style></author><author><style face="normal" font="default"> Iengo,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of sodium hyluronate added to topical corticosteroids in chronic rhinosinusitis with nasal polyposis</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="343" start="340">340-343</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angiogenesis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> mometasone furoate</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal cytology</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Available medical treatments for chronic rhinosinusitis (CRS) with nasal polyposis (CRSwNP) comprise systemic and topical therapies. Although topical corticosteroids are effective in the treatment of CRS, they are not completely devoid of adverse effects. Thus, care has to be taken when long-term treatments are prescribed. There is recent evidence that sodium hyaluronate (SH), the major component of many extracellular matrices, promotes tissue healing, including activation and moderation of the inflammatory responses, cell proliferation, migration, and angiogenesis. OBJECTIVE: The aim of the study was to evaluate clinical outcomes and quality of life in two groups of patients with CRSwNP treated with topical corticosteroids alone or in combination with 9 mg of high-molecular-weight SH. METHODS: The impact of treatments was determined by using nasal endoscopy and validated quality of life questionnaires (Short Form-36, 22-item Sino-Nasal Outcome Test, visual analog scale [VAS]). Eighty subjects who had CRS with grade IV nasal polyposis: 40 diagnosed with allergic rhinitis (AR) and 40 with non-allergic-eosinophilic rhinitis (NARES) based on skin-prick test and nasal cytology results, were divided in two groups. Group I comprised 40 subjects (20 AR and 20 NARES), who received mometasone furoate plus SH; group II comprised 40 subjects (20 AR and 20 NARES), who received mometasone furoate plus saline solution alone. All the patients were followed up for 3 months. RESULTS: At baseline, no statistically significant differences were observed between the groups and the VAS score showed a moderate-to-severe degree of disease. After treatments, Lund and Kennedy, Short Form-36, 22-item Sino-Nasal Outcome Test, and VAS scores were statistically significant in both groups but slightly in favor of the group I and in the subjects with allergic CRSwNP. CONCLUSION: Analysis of our data indicated that an SH supplement to standard corticosteroid seems to play an important role in improving the severity of symptoms, the endoscopic appearance, and discomfort associated with CRSwNP. This effect seems to be strongest in patients with allergic CRSwNP</style></abstract><notes><style face="normal" font="default">DA - 20160615IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2016.30.4344</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27302143">PM:27302143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2016-30-340-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2016-30-340-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160615, Cantone E</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2016.30.4344</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manu,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hofstra Northwell School of Medicine, Hempstead, NY</style></auth-address><titles><title><style face="normal" font="default">Broad-Spectrum Beta-Lactams for Patients Allergic to Penicillin</style></title><secondary-title><style face="normal" font="default">Am J Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Ther</style></full-title></periodical><pages end="" start="e979">e979-</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160708IS - 1536-3686 (Electronic)IS - 1075-2765 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MJT.0000000000000471</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27386960">PM:27386960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Ther\2016-23-e979.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Ther\2016-23-e979.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160708, Manu P</style></custom2><misc3><style face="normal" font="default">10.1097/MJT.0000000000000471</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patel,T.A.</style></author><author><style face="normal" font="default"> Lukawska,J.</style></author><author><style face="normal" font="default"> Rowe,J.</style></author><author><style face="normal" font="default"> Bailey,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital for Tropical Diseases, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Treatment of Schistosomiasis in a Patient Allergic to Praziquantel: A Praziquantel Desensitization and Treatment Protocol</style></title><secondary-title><style face="normal" font="default">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Trop Med Hyg</style></full-title></periodical><pages end="1043" start="1041">1041-1043</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Praziquantel</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Rapid desensitization</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Schistosomiasis</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="default">Praziquantel is the mainstay of treatment of Schistosomiasis, which affects at least 262 million people worldwide. It is also used in the treatment of other trematode as well as cestode infections, with few safe and effective alternatives. It is generally well tolerated and allergic reactions are rare. In this report, we present a case of schistosomiasis with a history of a hypersensitivity reaction to praziquantel. Skin-prick and intradermal testing were performed, followed by treatment through rapid desensitization. This protocol may be of value to those patients requiring praziquantel treatment with a history of IgE-mediated allergy to the drug</style></abstract><notes><style face="normal" font="default">DA - 20160830IS - 1476-1645 (Electronic)IS - 0002-9637 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.4269/ajtmh.16-0462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27573630">PM:27573630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Trop Med Hyg\2016-95-1041-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Trop Med Hyg\2016-95-1041-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160830, Patel TA</style></custom2><misc3><style face="normal" font="default">10.4269/ajtmh.16-0462</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hakozaki,T.</style></author><author><style face="normal" font="default"> Murakawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fukushima, JapanFukushima, Japan</style></auth-address><titles><title><style face="normal" font="default">Rocuronium-induced anaphylaxis not improved by low dose sugammadex: a case report</style></title><secondary-title><style face="normal" font="default">Anaesth Intensive Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anaesth Intensive Care</style></full-title></periodical><pages end="" start="522">522-</pages><volume><style face="normal" font="default">44</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Sugammadex</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160726IS - 0310-057X (Print)IS - 0310-057X (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456189">PM:27456189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesth Intensive Care\2016-4-522.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesth Intensive Care\2016-4-522.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160726, Hakozaki T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haybarger,E.</style></author><author><style face="normal" font="default"> Young,A.S.</style></author><author><style face="normal" font="default"> Giovannitti,J.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dentist Anesthesiologist, Greenville, South Carolina. Former Resident in Dental Anesthesiology, University of Pittsburgh, Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Benzodiazepine Allergy With Anesthesia Administration: A Review of Current Literature</style></title><secondary-title><style face="normal" font="default">Anesth Prog</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anesth Prog</style></abbr-1></periodical><pages end="167" start="160">160-167</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Bradycardia</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> dentist</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> South Carolina</style></keyword><keyword><style face="normal" font="default"> Tachycardia</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The incidence of anaphylactic/anaphylactoid reactions has been reported to vary between 1 : 3500 and 1 : 20,000 cases with a mortality rate ranging from 3 to 9%. Clinical signs present as skin rash, urticaria, angioedema, bronchospasm, tachycardia, bradycardia, and hypotension. Rapid identification and treatment are crucial to overall patient prognosis, as delayed intervention is associated with increased mortality. Diagnosis may be confirmed with clinical presentation, serum tryptase levels, and skin test results. While the main causative agents in anesthetic practice are typically neuromuscular blocking agents (NMBs), latex, and antibiotics, this review aims to discuss recognition, management, and preventive measures in perioperative anaphylactic/anaphylactoid reactions from benzodiazepine administration</style></abstract><notes><style face="normal" font="default">DA - 20160902IS - 0003-3006 (Print)IS - 0003-3006 (Linking)LA - engPT - Journal ArticleSB - DCO - United States -</style></notes><work-type><style face="normal" font="default">10.2344/16-00019.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27585420">PM:27585420</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anesth Prog\2016-63-160-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anesth Prog\2016-63-160-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160902, Haybarger E</style></custom2><misc3><style face="normal" font="default">10.2344/16-00019.1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sulaiman,I.</style></author><author><style face="normal" font="default"> Seheult,J.</style></author><author><style face="normal" font="default"> MacHale,E.</style></author><author><style face="normal" font="default"> Boland,F.</style></author><author><style face="normal" font="default"> O'Dwyer,S.M.</style></author><author><style face="normal" font="default"> Rapcan,V.</style></author><author><style face="normal" font="default"> D'Arcy,S.</style></author><author><style face="normal" font="default"> Cushen,B.</style></author><author><style face="normal" font="default"> Mokoka,M.</style></author><author><style face="normal" font="default"> Killane,I.</style></author><author><style face="normal" font="default"> Ryder,S.A.</style></author><author><style face="normal" font="default"> Reilly,R.B.</style></author><author><style face="normal" font="default"> Costello,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Royal College of Surgeons Ireland, Respiratory Department, Dublin , Dublin, Ireland</style></auth-address><titles><title><style face="normal" font="default">A Method to Calculate Adherence to Inhaled Therapy That Reflects the Changes in Clinical Features of Asthma</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="1903" start="1894">1894-1903</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="default">Rationale Currently studies on adherence to inhaled medications report Average Adherence over time. This measure does not account for variations in the interval between doses nor for errors in inhaler use. Objectives We investigated whether adherence calculated as a single Area Under the concentration-time Curve (AUC) measure, incorporating the interval between doses and inhaler technique, was more reflective of patient outcomes than current methods of assessing adherence. Methods We attached a digital audio device (INCATM) to a dry powder inhaler. This recorded when the inhaler was used and analysis of the audio data indicated if the inhaler had been used correctly. These aspects of inhaler use were combined to calculate adherence over time, as an AUC measure. Over a 3 month period a cohort of asthma patients were studied. Adherence to a twice-daily inhaler preventer therapy using this device and clinical measures were assessed. Measurements and Results Recordings from 239 patients with severe asthma were analysed. Average Adherence, based on the dose counter was 84.4%, whereas the ratio of expected to observed accumulated AUC, Actual Adherence, was 61.8% (p&lt;0.01). Of all adherence measures, only adherence calculated as AUC reflected changes in asthma quality of life, beta agonist reliever use and PEF, over the three months (p&lt;0.05 compared to other measures of adherence). Conclusion Adherence that incorporates the interval between doses and inhaler technique, and calculated as AUC, is more reflective of changes in quality of life and lung function than the currently used measures of adherence</style></abstract><notes><style face="normal" font="default">DA - 20160728IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Ireland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201603-222OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27467125">PM:27467125</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\20160728-SulaimanI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\20160728-SulaimanI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160728, Sulaiman I</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201603-222OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mikkelsen,A.</style></author><author><style face="normal" font="default"> Galli,C.</style></author><author><style face="normal" font="default"> Eiben,G.</style></author><author><style face="normal" font="default"> Ahrens,W.</style></author><author><style face="normal" font="default"> Iacoviello,L.</style></author><author><style face="normal" font="default"> Molnar,D.</style></author><author><style face="normal" font="default"> Pala,V.</style></author><author><style face="normal" font="default"> Rise,P.</style></author><author><style face="normal" font="default"> Rodriguez,G.</style></author><author><style face="normal" font="default"> Russo,P.</style></author><author><style face="normal" font="default"> Tornaritis,M.</style></author><author><style face="normal" font="default"> Veidebaum,T.</style></author><author><style face="normal" font="default"> Vyncke,K.</style></author><author><style face="normal" font="default"> Wolters,M.</style></author><author><style face="normal" font="default"> Mehlig,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section for Epidemiology and Social Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SwedenSection for Epidemiology and Social Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="default">Blood fatty acid composition in relation to allergy in children aged 2-9 years: results from the European IDEFICS study</style></title><secondary-title><style face="normal" font="default">Eur J Clin Nutr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Clin Nutr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Breast Feeding</style></keyword><keyword><style face="normal" font="default"> Breast-feeding</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Estonia</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Oleic Acid</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Health Care</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="21" Month="9" Year="2016">2016/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: Blood polyunsaturated fatty acids (PUFA) are involved in allergy development, but the etiological role of n-6 and n-3 PUFA is still controversial. A European multicenter study of children (IDEFICS) provided the opportunity to explore the cross-sectional association between fatty acids (FA) and allergy. SUBJECTS/METHODS: Blood FA levels were measured in 2600 children aged 2-9 years and were recorded as the percentage of weight of all FA detected. Logistic regression of allergy status on FA components was adjusted for age, sex, country, body mass index, family history of allergic disease, breast-feeding, and number of siblings. The results were given as odds ratios (OR) for current vs no allergy ever and an increase in FA by 1 s.d. RESULTS: Overall, higher proportions of n-6 PUFA were associated with higher odds of allergy (OR=1.21 (1.05, 1.40)). Monounsaturated FA (MUFA) were associated with reduced risk for allergy (OR=0.75 (0.65, 0.87)), whereas saturated FA did not differ by allergy status. The strongest associations were observed in children &lt;4 years old, with ORs of allergy given as 1.62 (1.15, 2.29) for n-3 PUFA and 0.63 (0.42, 0.95) for MUFA. With regard to individual FA, these associations were independently observed for docosapentaenoic acid (22:5 n-3) and oleic acid (18:1 n-9). CONCLUSIONS: Both PUFA subtypes were positively associated with allergy in an age-dependent manner, whereas MUFA was associated with less allergy. The observation of high proportions of n-3 PUFA in allergic children younger than 4 years might help to understand the nature of early onset of atopic disease.European Journal of Clinical Nutrition advance online publication, 21 September 2016; doi:10.1038/ejcn.2016.158</style></abstract><notes><style face="normal" font="default">DA - 20160921IS - 1476-5640 (Electronic)IS - 0954-3007 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -CO - Italy -CO - Germany -CO - Hungary -CO - Spain -CO - Cyprus -CO - Estonia -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1038/ejcn.2016.158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27650873">PM:27650873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Clin Nutr\20160921-MikkelsenA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Clin Nutr\20160921-MikkelsenA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160921, Mikkelsen A</style></custom2><misc3><style face="normal" font="default">10.1038/ejcn.2016.158</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papaioannou,A.I.</style></author><author><style face="normal" font="default"> Spathis,A.</style></author><author><style face="normal" font="default"> Kostikas,K.</style></author><author><style face="normal" font="default"> Karakitsos,P.</style></author><author><style face="normal" font="default"> Papiris,S.</style></author><author><style face="normal" font="default"> Rossios,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">2nd Respiratory Medicine Department, "Attikon" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Greece.</style></auth-address><titles><title><style face="normal" font="default">The role of endosomal toll-like receptors in asthma</style></title><secondary-title><style face="normal" font="default">Eur J Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> aeroallergens</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Ligation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> therapy of asthma</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> TLR7</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword></keywords><dates><year Day="24" Month="9" Year="2016">2016/9/24</year></dates><abstract><style face="normal" font="default">Asthma is a heterogeneous inflammatory disease caused by association of genetic and environmental factors and its incidence has significantly increased over the latest years. The clinical manifestations of asthma are the result of airway hyper-reactivity to a variety of triggers such as aeroallergens, viral and bacterial components. Toll-like receptors (TLRs) are pathogen associated molecular pattern receptors, which are also expressed in the lung tissue as well as in several cells of the innate and adaptive immune system. Ligation of TLRs results in alterations in the expression of several inflammatory and anti-inflammatory mediators, which are known to be involved in the pathogenesis of asthma. The endosomal TLRs have been shown to be associated with the induction of asthmatic inflammation (TLR3), and with disease exacerbations (TLR7, TLR8 and TLR9). Targeting these receptors seems to be an effective choice for suppressing airway inflammation, eosinophilia and airway hyperresponsiveness in asthmatic patients. In this review we provide information regarding endosomal TLRs and their role in the pathogenesis of asthma as well as their potential use as targets for the development of novel treatments for the therapy of asthma</style></abstract><notes><style face="normal" font="default">DA - 20160928IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Greece -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.ejphar.2016.09.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27677226">PM:27677226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Pharmacol\20160928-PapaioannouAI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Pharmacol\20160928-PapaioannouAI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160928, Papaioannou AI</style></custom2><misc3><style face="normal" font="default">10.1016/j.ejphar.2016.09.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.H.</style></author><author><style face="normal" font="default"> Son,J.</style></author><author><style face="normal" font="default"> Nam,H.J.</style></author><author><style face="normal" font="default"> Ko,S.G.</style></author><author><style face="normal" font="default"> Choi,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; Department of Otorhinolaryngology of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of KoreaDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Hyeonggaeyeongyo-Tang for Treatment of Allergic and Nonallergic Rhinitis: A Prospective, Nonrandomized, Pre-Post Study</style></title><secondary-title><style face="normal" font="default">Evid Based Complement Alternat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Evid Based Complement Alternat Med</style></full-title></periodical><pages end="" start="9202675">9202675-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic rhinitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Rhinoconjunctivitis Quality of Life Questionnaire</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Hyeonggaeyeongyo-tang (HYT) is an ancient formula of oriental medicine traditionally used to treat rhinitis; however, clinical evidence has not yet been established. The aim of this study was to investigate the short-term and long-term efficacy and safety of HYT for chronic rhinitis. Adult subjects with chronic rhinitis symptoms were recruited. The subjects received HYT for 4 weeks and had follow-up period of 8 weeks. Any medicines used to treat nasal symptoms were not permitted during the study. The skin prick test was performed to distinguish the subjects with allergic rhinitis from those with nonallergic rhinitis. After treatment, the total nasal symptoms score and the Rhinoconjunctivitis Quality of Life Questionnaire score significantly improved in the whole subject group, in the allergic rhinitis group, and in the nonallergic rhinitis group, with no adverse events. This improvement lasted during a follow-up period of 8 weeks. Total IgE and eosinophil levels showed no significant difference after treatment in the allergic rhinitis group. HYT improved nasal symptoms and quality of life in patients with allergic rhinitis and nonallergic rhinitis. This is the first clinical study to evaluate the use of HYT to treat patients with rhinitis. This trial has been registered with the ClinicalTrials.gov Identifier NCT02477293</style></abstract><notes><style face="normal" font="default">DA - 20161004IS - 1741-427X (Print)IS - 1741-427X (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1155/2016/9202675</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27698676">PM:27698676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2016-2016-9202675.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2016-2016-9202675.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161004, Kim MH</style></custom2><misc3><style face="normal" font="default">10.1155/2016/9202675</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,J.G.</style></author><author><style face="normal" font="default"> Chen,X.J.</style></author><author><style face="normal" font="default"> Liu,T.</style></author><author><style face="normal" font="default"> Jiang,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China</style></auth-address><titles><title><style face="normal" font="default">FOXP3+ associated with the pro-inflammatory regulatory T and T helper 17 effector cells in asthma patients</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="2758" start="2753">2753-2758</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial inflammation</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Asthma is a chronic bronchial inflammation that results to reversible incidence of airway obstruction and shortness of breath. Under normal circumstances, the lung immune system is maintained in a state of controlled inflammation, where balance exists between protective immunity mediated by effector cells and tolerance mediated by cells with regulatory function. Therefore, the inflammation observed in asthma patients may be caused by an imbalance between regulatory T (Treg) cells (CD4-positive with high expression of CD25 surface markers) and forkhead box P3 (FOXP3)-positive pro-inflammatory T helper 17 (Th17) cells. The aim of the present study was to evaluate whether reduced Treg cells and increased Th17 cells could be observed in the peripheral blood samples of asthma patients. As important markers of Treg cells, the expression levels of FOXP3 and interleukin (IL)-17a were analyzed via reverse trancription-quantitative polymerase chain reaction. The results indicated that the levels of cytokines that promote Th17 cells, including IL-6, IL-23 and TGF-beta, were found to increase in the bronchoalveolar lavage fluid sample of asthma patients. However, the IL-10 level in the corresponding sample was much lower compared with that in control individuals. In conclusion, these results suggest that asthma associated with a reduced proportion of Treg and Th17 cells in the blood is characterized by the expression of pro-inflammatory cytokines that may be beneficial for the continuous generation of Th17 cells</style></abstract><notes><style face="normal" font="default">DA - 20161005IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2016.3662</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27703517">PM:27703517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2016-12-2753-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2016-12-2753-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161005, Zhang JG</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2016.3662</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhu,Z.</style></author><author><style face="normal" font="default"> Xie,Y.</style></author><author><style face="normal" font="default"> Guan,W.</style></author><author><style face="normal" font="default"> Gao,Y.</style></author><author><style face="normal" font="default"> Xia,S.</style></author><author><style face="normal" font="default"> Zhong,N.</style></author><author><style face="normal" font="default"> Zheng,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">State Key Laboratory of Respiratory Disease, China Clinical Research Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China</style></auth-address><titles><title><style face="normal" font="default">FeNO for detecting lower airway involvement in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="2340" start="2336">2336-2340</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Allergic rhinitis (AR) is a risk factor for asthma development. The value of fractional exhaled nitric oxide (FeNO) in detecting lower airway involvement in the progress of AR-asthma march has not been evaluated. The aim of the present study was to investigate the value of FeNO in assessing lower airway inflammation and predicting bronchial hyperresponsiveness (BHR) in AR with or without asthma. FeNO and eosinophil count in induced sputum, and a methacholine bronchial provocation test were performed in 93 subjects, including: 45 AR patients (AR group); 20 patients with AR and asthma (AR with asthma group); and 28 normal controls (control group). The AR group was divided into two sub-groups: AR with asymptomatic BHR group and AR without BHR group. Correlation between FeNO and eosinophil count was assessed. Receiver operating characteristic (ROC) curve was applied to evaluate the predictive and diagnostic value of FeNO in detecting BHR. The values of FeNO in the AR and AR with asthma groups were higher [29.5 (22.0) ppb and 61.5 (33.0) ppb] compared with the normal control group (16.0 (10.0) ppb), where the values in brackets indicate the interquartile range of the values. The percentages of eosinophils in induced sputum were 2.43+/-3.56, 7.36+/-4.98 and 18.58+/-11.26% in the control, AR and AR with asthma groups, respectively. For the diagnosis of BHR, the area under the curve (AUC) was 0.910 (95%CI 0.836, 0.984), with the sensitivity and specificity 0.846 and 0.817 when the cut-off value takes 31.5 ppb. For diagnosis of asthma, the AUC was 0.873 (95%CI 0.753, 0.992) with sensitivity 0.857 and specificity 0.847 when taking the cut-off value to be 38.0 ppb. The value of FeNO was well correlated with eosinophil count in the sputum. The measurement of FeNO is an effective method in detecting lower airway involvement in AR developing to asthma</style></abstract><notes><style face="normal" font="default">DA - 20161005IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2016.3616</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27703499">PM:27703499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2016-12-2336-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2016-12-2336-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161005, Zhu Z</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2016.3616</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eaaswarkhanth,M.</style></author><author><style face="normal" font="default"> Xu,D.</style></author><author><style face="normal" font="default"> Flanagan,C.</style></author><author><style face="normal" font="default"> Rzhetskaya,M.</style></author><author><style face="normal" font="default"> Hayes,M.G.</style></author><author><style face="normal" font="default"> Blekhman,R.</style></author><author><style face="normal" font="default"> Jablonski,N.</style></author><author><style face="normal" font="default"> Gokcumen,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biological Sciences, University at Buffalo, The State University of New York at Buffalo, Buffalo, NY 14260</style></auth-address><titles><title><style face="normal" font="default">Atopic Dermatitis Susceptibility Variants In Filaggrin Hitchhike Hornerin Selective Sweep</style></title><secondary-title><style face="normal" font="default">Genome Biol Evol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Genome Biol Evol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> haplotype</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="27" Month="9" Year="2016">2016/9/27</year></dates><abstract><style face="normal" font="default">Human skin has evolved rapidly, leaving evolutionary signatures in the genome. The filaggrin (FLG) gene is widely studied for its skin-barrier function in humans. The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis. To investigate the evolution of this gene, we analyzed 2,504 human genomes and genotyped the copy number variation of filaggrin repeats within FLG in 126 individuals from diverse ancestral backgrounds. We were unable to replicate a recent study claiming that LoF of FLG is adaptive in northern latitudes with lower ultraviolet light exposure. Instead, we present multiple lines of evidence suggesting that FLG genetic variation, including LoF variants, have little or no effect on fitness in modern humans. Haplotype-level scrutinization of the locus revealed signatures of a recent selective sweep in Asia, which increased the allele frequency of a haplotype group (Huxian haplogroup) in Asian populations. Functionally, we found that the Huxian haplogroup carries dozens of functional variants in FLG and hornerin (HRNR) genes, including those that are associated with atopic dermatitis susceptibility, HRNR expression levels and microbiome diversity on the skin. Our results suggest that the target of the adaptive sweep is HRNR gene function, and the functional FLG variants that involve susceptibility to atopic dermatitis, seem to hitchhike the selective sweep on HRNR Our study presents a novel case of a locus that harbors clinically relevant common genetic variation with complex evolutionary trajectories</style></abstract><notes><style face="normal" font="default">DA - 20160928IS - 1759-6653 (Electronic)IS - 1759-6653 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1093/gbe/evw242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27678121">PM:27678121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Genome Biol Evol\20160928-EaaswarkhanthM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Genome Biol Evol\20160928-EaaswarkhanthM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160928, Eaaswarkhanth M</style></custom2><misc3><style face="normal" font="default">10.1093/gbe/evw242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mancano,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ipilimumab-Induced Polyneuropathy; Ibuprofen-Induced Allergic-Type Liver Injury; Trimethoprim-Sulfamethoxazole-Induced Immune Thrombocytopenia in Children; Mesna-Induced Fixed Drug Eruption; Digoxin-Induced Ocular Toxicity</style></title><secondary-title><style face="normal" font="default">Hosp Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hosp Pharm</style></abbr-1></periodical><pages end="627" start="623">623-627</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Fixed drug eruption</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Polyneuropathies</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner</style></abstract><notes><style face="normal" font="default">DA - 20161004IS - 0018-5787 (Print)IS - 0018-5787 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1310/hpj5108-623</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27698499">PM:27698499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hosp Pharm\2016-51-623-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hosp Pharm\2016-51-623-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161004, Mancano AA</style></custom2><misc3><style face="normal" font="default">10.1310/hpj5108-623</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wiese,A.V.</style></author><author><style face="normal" font="default"> Ender,F.</style></author><author><style face="normal" font="default"> Sun,J.</style></author><author><style face="normal" font="default"> Vollbrandt,T.</style></author><author><style face="normal" font="default"> Konig,P.</style></author><author><style face="normal" font="default"> Kohl,J.</style></author><author><style face="normal" font="default"> Laumonnier,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">The C5a/C5aR1 axis is critical for the activation of a novel vacuolated eosinophil population in experimental allergic asthma</style></title><secondary-title><style face="normal" font="default">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunobiology</style></full-title></periodical><pages end="" start="1200">1200-</pages><volume><style face="normal" font="default">221</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><isbn><style face="normal" font="default">0171-2985</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.imbio.2016.06.168</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.imbio.2016.06.168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunobiology\2016-221-1200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunobiology\2016-221-1200.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Wiese AV</style></custom2><misc3><style face="normal" font="default">10.1016/j.imbio.2016.06.168</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ender,F.</style></author><author><style face="normal" font="default"> Wiese,A.V.</style></author><author><style face="normal" font="default"> Vollbrandt,T.</style></author><author><style face="normal" font="default"> Kohl,J.</style></author><author><style face="normal" font="default"> Laumonnier,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">A dual role of C5a for initial CD11b+ dendritic cell accumulation and activation in experimental allergic asthma</style></title><secondary-title><style face="normal" font="default">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunobiology</style></full-title></periodical><pages end="" start="1192">1192-</pages><volume><style face="normal" font="default">221</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><isbn><style face="normal" font="default">0171-2985</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.imbio.2016.06.150</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.imbio.2016.06.150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunobiology\2016-221-1192.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunobiology\2016-221-1192.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Ender F</style></custom2><misc3><style face="normal" font="default">10.1016/j.imbio.2016.06.150</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kandowishi,R.F.</style></author><author><style face="normal" font="default"> Mukesi,M.</style></author><author><style face="normal" font="default"> Moyo,S.R.</style></author><author><style face="normal" font="default"> Erxun,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">An Investigation of the Occurrence of Atopic Dermatitis in Khomas Region School Children, Windhoek, Namibia</style></title><secondary-title><style face="normal" font="default">Int J Allergy Medic</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Allergy Medic</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Developed Countries</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Namibia</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The aetiology of atopic dermatitis remains poorly understood in Namibia despite considerable research in other developing and developed countries. Although there is growing knowledge about factors that may predispose to the onset of atopic dermatitis (AD), as well as factors which may exacerbate existing disease among school children in Namibia very little is known about the epidemiology of atopic dermatitis (AD), and studies from Southern Africa and Namibia in particular are limited. The researcher sought to investigate the frequency, and perceived risk factors associated with AD, asthma, rhinitis and dermatitis in children living the Khomas region, Namibia.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -CO - Namibia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://clinmedjournals.org/published_articles.php?jid=ijam</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Allergy Medic\20161025-KandowishiRF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Allergy Medic\20161025-KandowishiRF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Kandowishi RF</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Christensen,B.H.</style></author><author><style face="normal" font="default"> Schlunssen,V.</style></author><author><style face="normal" font="default"> Thulstrup,A.M.</style></author><author><style face="normal" font="default"> Hougaard,K.S.</style></author><author><style face="normal" font="default"> Hansen,K.S:</style></author><author><style face="normal" font="default"> Skadhauge,L.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Occupational Exposure During Pregnancy and the Risk of Atopic Dermatitis in the Offspring</style></title><secondary-title><style face="normal" font="default">Int J Clin Med Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Clin Med Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> Maternal Exposure</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: The prevalence of atopic dermatitis (AD) has increased considerably in the last decades. The major predisposing factor for AD is an inherited epithelial barrier defect due to loss-of-function in the filaggrin gene. Environmental factors are also hypothesised to cause AD. The aim of the present study was to analyse whether maternal occupational exposure to allergens or irritants during pregnancy is associated with AD in the offspring.Methods: A total of 41,724 mother-child pairs from The Danish National Birth Cohort were categorized according to maternal occupational exposure assessed by combining occupation during pregnancy and a job exposure matrix. AD in the offspring was defined by a combination of parentally reported AD and eczema in locations typical for AD.Results: AD was identified in 14.9% and 11.7% of the children by age 18 months and 7 years, respectively. By age 18 months, maternal mixed low- and high molecular weight agents exposure (health care workers) during pregnancy was positively associated with AD (OR 1.07 (95% CI: 0.98-1.16)). Maternal exposure to low molecular weight agents showed a borderline significantly decreased risk of AD (OR 0.88 (0.78-1.00)). By age 7, none of the maternal exposure groups were associated with a changed risk of AD in the offspring.Conclusions: Our results do not suggest maternal exposure during pregnancy to be a significant risk factor for AD in the offspring. Exposure of pregnant women employed in the healthcare sector to e.g. antibiotics, latex and cleaning agents might pose a risk factor for AD in their offspring.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.19070/2332-2799-150006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.19070/2332-2799-150006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-ChristensenBH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-ChristensenBH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Christensen BH</style></custom2><misc3><style face="normal" font="default">10.19070/2332-2799-150006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maurer,L.B.</style></author><author><style face="normal" font="default"> Gonzalez-Estrada,A.</style></author><author><style face="normal" font="default"> Fernandez,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">A Delayed Presentation of Acute Generalized Exanthematous Pustulosis (AGEP)</style></title><secondary-title><style face="normal" font="default">Int J Clin Med Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Clin Med Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default"> Acute Generalized Exanthematous Pustulosis (AGEP) is a Type IVd hypersensitivity reaction that usually occurs within 1-5 days of drug exposure. The diagnosis is clinical and confirmed by skin biopsy. A scoring algorithm has been developed which assigns points to characteristic clinical signs in order to aid in the diagnosis. AGEP is a self-limited disease with a favorable prognosis in most cases. We present an unusual delayed presentation of AGEP secondary to hydroxycholoroquine.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.19070/2332-2799-150004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.19070/2332-2799-150004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-MaurerLB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-MaurerLB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Maurer LB</style></custom2><misc3><style face="normal" font="default">10.19070/2332-2799-150004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xhixha,F.</style></author><author><style face="normal" font="default"> Bakiri,A.H.</style></author><author><style face="normal" font="default"> Mingomataj,D.C.</style></author><author><style face="normal" font="default"> Ibranji,A.</style></author><author><style face="normal" font="default"> Gurakuqi,A.</style></author><author><style face="normal" font="default"> Mingomataj,E.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Risk Factors Exposure during the First Life Year and Asthma Development among Albanian Children</style></title><secondary-title><style face="normal" font="default">Int J Clin Med Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Clin Med Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Albania</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Breast Feeding</style></keyword><keyword><style face="normal" font="default"> Breast-feeding</style></keyword><keyword><style face="normal" font="default"> Cesarean Section</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: Different environmental factors are accused as risk factors (RF) in the development of allergic respiratory diseases. This study aimed to investigate the role of exposure to suspected RFs during the first life year in the development of childhood asthma among Albanian capital residents with a provincial or suburban origin.Method: Parental reports about own asthmatic children (276, m 160, f 116, aged 1-14, mean age 5.6) were collected regarding conduction of cesarean delivery, breast feeding, exposure to high house humidity, pets, or to passive tobacco smoke, and presence of familiar atopy or atopic dermatitis during the first life year. These results were compared with a sample of non-allergic children (100, m 49, f 51, mean age 5.7), diagnosed with common upper respiratory infections.Results: Conduction of cesarean section (OR = 9.8, p = 0.0002), exposure to high humidity at home (OR = 3.77, p = 0.0001), or to passive tobacco smoke (OR = 4.78, p &lt; 0.0001), as well as presence of atopic dermatitis (OR = 10.37, p = 0.0001) was significantly associated with asthma development. Familiar atopy (OR = 1.07) and exposure to pets (OR = 1.66) resulted insignificant, whereas breast feeding resulted in protective factor (OR = 0.48, p = 0.0134).Conclusion: Cesarean section during birth, increased humidity level at home, atopy and passive tobacco smoke during the first life year could be RFs regarding the asthma development. The avoidance of mentioned factors at least during the mentioned period may reduce the development risk of this disease.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Albania -</style></notes><work-type><style face="normal" font="default">10.19070/2332-2799-150008</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.19070/2332-2799-150008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-XhixhaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-XhixhaF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Xhixha F</style></custom2><misc3><style face="normal" font="default">10.19070/2332-2799-150008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lima,J.S.</style></author><author><style face="normal" font="default"> Santos,R.S.</style></author><author><style face="normal" font="default"> Ribeiro,B.M.</style></author><author><style face="normal" font="default"> Silva,M.H.</style></author><author><style face="normal" font="default"> Rodrigues,V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Immune Response Profiles During Asthma Attacks and Intercritical Periods In Children</style></title><secondary-title><style face="normal" font="default">Int J Clin Med Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Clin Med Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IgG4</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Asthma is a serious public health problem due to its socioeconomic impact worldwide and affects over three hundred million individuals. This chronic inflammatory airway disease causes hyperresponsiveness, obstruction, increased mucus production and airway remodeling. Due to research advances, our understanding of the pathophysiology of asthma has changed, as has our knowledge of the cells and mediators involved in the inflammation and remodeling that result from asthma exacerbations.The acknowledgement that asthma is much more than an inflammatory disorder that involves the T helper (Th)1-Th2 dichotomy led us to conduct the present study, which aims to determine the attack x intercritical period profile in patients with asthma. The study determined the cytokine (interleukin [IL] 1ß, IL-4, IL-5, IL-9, IL-10, IL-13, IL-15, IL-17 and interferon-gamma [IFN-?]), basophil, eosinophil and immunoglobulin (Ig) E and IgG4 profile in 30 children with asthma during attacks and in the intercritical period. The correlations between Th1 and Th2 and between Th17 and regulatory T cells (Treg) were analyzed, and no significant correlations were observed.We observed higher IL-15 and IFN? levels in patients with asthma than in controls, and no significant differences in IL-17 levels were observed when children with asthma and controls were compared.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.19070/2332-2799-150007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.19070/2332-2799-150007.</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-LimaJS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Clin Med Allergy\20161025-LimaJS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Lima JS</style></custom2><misc3><style face="normal" font="default">10.19070/2332-2799-150007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>39350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,Q.</style></author><author><style face="normal" font="default"> Fu,X.L.</style></author><author><style face="normal" font="default"> Qian,F.H.</style></author><author><style face="normal" font="default"> Cao,Q.</style></author><author><style face="normal" font="default"> Mao,Z.D.</style></author><author><style face="normal" font="default"> Bai,J.L.</style></author><author><style face="normal" font="default"> Du,Q.</style></author><author><style face="normal" font="default"> Shi,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Affiliated Changzhou No. 2 People's Hospital, Nanjing Medical University, Changzhou, China</style></auth-address><titles><title><style face="normal" font="default">Polymorphisms in Toll-like receptor 3 are associated with asthma-related phenotypes in the Chinese Han patients</style></title><secondary-title><style face="normal" font="default">Int J Immunogenet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Immunogenet</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Association</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> tagging single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="9" Year="2016">2016/9/29</year></dates><abstract><style face="normal" font="default">Toll-like receptor (TLR) 3 mediates antivirus immunity and is involved in asthma exacerbation and development. However, the genetic association between TLR3 and asthma remains unclear. This study aimed to evaluate the effects of polymorphisms within TLR3 on asthma risk and asthma-related phenotypes in the Chinese Han population. A total number of 462 unrelated adult patients with asthma and 398 healthy volunteers were enrolled in this study. The genotypes of tagging single nucleotide polymorphisms (SNPs) in TLR3 gene were determined using multiplex SNaPshot SNP genotyping assays. Case-control and case-only studies were used to assess any links with asthma and asthma-related phenotypes. The results showed that the genetic variants in TLR3 were associated with asthma-related phenotypes, including eosinophil counts, serum immunoglobulin E levels and lung function. However, there was no obvious association between the TLR3 SNPs and asthma susceptibility or asthma severity. TLR3 polymorphisms may play a considerable role in the pathogenesis of asthma. It will help in better understanding the pathogenesis of asthma and development of more effective strategies for the prevention, prediction and treatment of asthma</style></abstract><notes><style face="normal" font="default">DA - 20160929IS - 1744-313X (Electronic)IS - 1744-3121 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="default">10.1111/iji.12290</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27682462">PM:27682462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Immunogenet\20160929-ZhangQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Immunogenet\20160929-ZhangQ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160929, Zhang Q</style></custom2><misc3><style face="normal" font="default">10.1111/iji.12290</style></misc3></record></records></xml>
